Adult patients with severe CRSwNP treated with tezepelumab continued to receive benefit 24 weeks after treatment cessation.

Approval based on WAYPOINT Phase III results demonstrating reduced nasal polyp severity and nasal congestion, near-elimination of the need for surgery and significantly reduced systematic ...

Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...

Approval based on WAYPOINT Phase III results demonstrating reduced nasal polyp severity and nasal congestion, near-elimination of the need for surgery and significantly reduced systematic ...

Investing.com -- AstraZeneca and Amgen have received European Union approval for Tezspire as an add-on therapy for adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) who haven’t ...

On October 17, 2025, Amgen and AstraZeneca announced that the FDA has approved an additional indication for TEZSPIRE (tezepelumab-ekko) for the add-on maintenance treatment of inadequately controlled ...

Please provide your email address to receive an email when new articles are posted on . Mean Asthma Control Questionnaire-6 scores fell from 2.6 at baseline to 1.4 at week 52. 47.3% had partially or ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Waypoint REIT Ltd. ( (AU:WPR)) has shared ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update from Waypoint REIT Ltd. ( ...

Please provide your email address to receive an email when new articles are posted on . Patients with both chronic rhinosinusitis with nasal polyps and asthma experience greater disease severity and ...

Dublin, Oct. 22, 2025 (GLOBE NEWSWIRE) -- The "Nasal Polyps - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering. The Nasal Polyps - Pipeline Insight, 2025 report offers ...

Female sex is associated with up to 44% increased odds of chronic rhinosinusitis without nasal polyps (CRSsNP), but 37% reduced odds of chronic rhinosinusitis with nasal polyps (CRSwNP), with lower ...